CVRx (CVRX) Expected to Announce Earnings on Thursday

CVRx (NASDAQ:CVRX) is anticipated to post its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.52) per share and revenue of $15.5490 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

CVRx (NASDAQ:CVRX) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.01. CVRx had a negative net margin of 89.14% and a negative return on equity of 120.76%. The business had revenue of $14.77 million during the quarter, compared to analyst estimates of $14.49 million. On average, analysts expect CVRx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CVRx Stock Down 0.2%

Shares of NASDAQ:CVRX opened at $5.49 on Wednesday. The stock has a market capitalization of $145.70 million, a P/E ratio of -2.72 and a beta of 0.81. The stock’s 50-day moving average price is $5.25 and its 200-day moving average price is $6.51. The company has a current ratio of 10.20, a quick ratio of 8.89 and a debt-to-equity ratio of 2.01. CVRx has a 12-month low of $4.37 and a 12-month high of $11.30.

Institutional Trading of CVRx

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC bought a new position in shares of CVRx in the 4th quarter worth approximately $79,000. Corient Private Wealth LLC purchased a new stake in shares of CVRx in the 4th quarter worth about $81,000. XTX Topco Ltd bought a new position in shares of CVRx in the 4th quarter worth about $90,000. Alliancebernstein L.P. increased its stake in shares of CVRx by 10.7% in the 3rd quarter. Alliancebernstein L.P. now owns 17,560 shares of the company’s stock worth $142,000 after acquiring an additional 1,700 shares in the last quarter. Finally, Wells Fargo & Company MN increased its stake in shares of CVRx by 61.3% in the 4th quarter. Wells Fargo & Company MN now owns 20,266 shares of the company’s stock worth $144,000 after acquiring an additional 7,705 shares in the last quarter. 75.27% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CVRX has been the topic of several recent research reports. Weiss Ratings lowered CVRx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Wall Street Zen upgraded CVRx from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $10.00 price objective on shares of CVRx in a research report on Tuesday, April 14th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, CVRx presently has an average rating of “Moderate Buy” and a consensus target price of $11.50.

CVRx Company Profile

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.